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ABSTRACT 
Vitamin B6 metabolism and transport were investigated using 
activation of erythrocyte aspartate apotransaminase (EGOT) as a 
measure of intracellular availability of active cofactor forms of B6. 
Questions asked here address the possibility that a form of B6 other 
than pyridoxal or pyridoxal-51-phosphate (PLP) is important in plasma 
and that entry of PLP into tissues may not involve mechanisms 
previously proposed. In plasma, two forms of vitamin B6, 
pyridoxamine-51-phosphate and pyridoxamine, were found to increase 
EGOT activity to a greater extent than other vitamers. Consistent 
with previous findings, it v/as also found that the presence of plasma 
inhibits EGOT activation by PLP. Further investigations of EGOT 
activation by PLP v/ith two anion channel blocking agents suggest that 
anion channels may play a role in PLP transport into the erythrocyte 
only at high PLP concentrations. This is in contrast to previous 
reports suggesting PLP entry into erythrocytes is entirely dependent 
on anion channels. 
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INTRODUCTION I . 
Over the past fifteen years, much attention has been focused on 
Vitamin B6 metabolism and transport in vivo and in vitro in an 
attempt to discern on a cellular level how the entire organism 
utilizes this essential cofactor. Unresolved in the current 
literature are questions regarding the relative importance of the 
various forms of B6, the overall effect of the non-cofactor 
interaction of the aldehyde forms of B6 with plasma and intracellular 
proteins, and the mode of B6 transport into tissues. 
The term "Vitamin Bs" is designated to include three different 
molecular forms and their phosphorylated derivatives known together 
as the B6 vitamers (IUPAC-IUB Commission on Biochemical Nomenclature 
1973). These are: pyridoxine (PN), pyridoxine 5'-phosphate (PNP), 
pyridoxamine (PM), qyridoxamine 5'-phosphate (PMP), pyridoxal (PL), 
and pyridoxal 5'-phosphate (PLP) (fig 1). Normal human plasma 
concentrations of the six B6 vitamers as measured by chromatography 
and fluorometric analysis (Lumeng et al 1930) are shown in Table 1. 
It is generally recognized however that of the six vitamers, only PLP 
and in some cases PMP are active cofactors at the enzymatic level 
(Meister et al 1954). The majority of enzymes requiring B6 as a 
cofactor are essential to amino acid metabolism. These include 
transaminases, synthetases, hydroxylases, decarboxylases and 
dehydratases. In addition, glycogen phosphorylase in muscle and 
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Figure 2. Schiff base formation. 

Table 1. . B6 vitamer concentrations. 
Total: 124 +/- 29nM (100%) 
PLP : 77 nil (62%) 
PN : 19 nH (15%) 
PL : 17 nM (14%) 
PH : 6 nM (5%) 
PMP : 5 nM (4%) 
delta-amino levulenic acid synthetase in the marrow require B6 for 
activation. 
A deficiency of vitamin B6 is known to produce dermatitis, anemia, 
neuropathy, convulsions, renal and hepatic function changes, 
decreased growth and decreased antibody formation (Sauberlich and 
Canham 1980). Additionally, in the alcoholic patient, B6 deficiency 
has been implicated in liver disease, peripheral neuropathy, 
convulsions, and sideroblastic anemia (Hines and Cowan 1970, Bonjour 
1980). In fact, even without exposure to alcohol, B6 deficiency has 
been shown to produce fatty infiltration and cirrhosis of the liver 
in monkeys (Greenberg 1964, Abe and Kishino 1982). There have also 
been suggestions that B6 status is related to nephrolithiasis, 
atherosclerosis, caries, altered hemostasis, and immunologic changes 
(Greenberg 1964, Sauberlich and Canham 1980). Nonetheless, a precise 
daily dietary requirement of vitamin B6 has not been established. 
The vitamin B6 requirement has been estimated to be 1.5 mg of 
3 
/ 
pyridoxine per 100 gm of dietary protein which translates into an RDA 
of 1.6-2.2 mg of PN per day depending on age and sex (Committee on 
Dietary Allowances, 1980). No signs or symptoms of PN toxicity are 
presently recognized in adults. However, studies with beagles given 
150mg/kg/day demonstrated neurological changes v/ithin two to six 
weeks (Hoover and Carlton 1981) and Unna1s (1940) early observations 
with rats showed 3gm/kg of PN produces convulsions and death within 
24 hours. 
Much of the interest in vitamin B6 pharmacology and metabolism 
originates from suggestions of its usefulness in therapy of certain 
vitamin B6-responsive disorders (i.e. dependency states). In 
addition, B6 therapy may be required for the treatment of simple 
deficiency states due to disorders of absorption and utilization. 
Specifically, pyridoxine administration has been shown to be 
helpful in certain gases of sideroblastic anemia, homocystinuria, and 
drug induced defiencies (i.e. secondary to INH, hydralazine, 
cycloserine, penicillamine, or oral contraceptive administration). 
Additionally, it has been suggested that hepatic cell damage 
secondary to alcohol abuse may be responsive to B6 administration 
(Lumeng and Li 1974, Bonjour 1980) and that sickle cell disease 
patients may benefit from pharmacological doses of B6 because of the 
in vitro anti-sickling effect of pyridoxal and pyridoxal phosphate 
(Zaugg et al 1977, Kark et al 1978). Thus, the importance of 
elucidating the precise mechanisms of B6 metabolism and hov; they may 
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be advantageously manipulated is underscored. 
Identification of the particular B6 vitamers which are most able 
to produce a desired response is essential. Pyroxidine is the B6 
vitamer presently used pharmacologically and orally administered PN 
is well absorbed from the jejunem (Brain and Booth 1964). Although 
Anderson (1980) argues that erythrocytes are a major site of PN 
oxidation to PL, Lumeng, et al (1980) demonstrate that the liver is 
primarily responsible for PN metabolism resulting in a net rise in 
plasma concentrations of PL, PLP, and the inactive metabolite, 
pyridoxic acid. This group further reports that administration of 
lOOmg of pyridoxine per day for three weeks to healthy adults results 
in a steady state level within one week of a six to seven-fold rise 
in plasma PLP concentration and a twelve-fold rise in PL 
concentration. At the tissue level, orally administered PN produces 
a sharp rise within hours in PL and PLP concentrations within the RBC 
(Anderson et al 1971). 
Important to the understanding of B6 vitamer activities 
intracellularly and in plasma is the covalent binding of PL and PLP 
to proteins. The reversible Schiff base formation by aldehydes with 
primary amines at neutral pH's is a well described reaction first 
recognized over a century ago (fig 2, Schiff 1864). Christensen 
(1958) first proposed the binding of the aldehyde forms of B6, PL and 
PLP, to the free amino groups of bovine serum albumin by Schiff base 
formation. Subsequently, he and his coworkers were able to 
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demonstrate the binding of PLP to albumin in a molar ratio of two to 
one (Dempsey 1962). Borohydride reduction followed by protein 
hydrolysis revealed the binding by PLP to be with two epsilon-amino 
groups of lysine residues. These findings were later confirmed to be 
the case with human albumin (Lumeng et al 1974, and Anderson et al 
1974). Lumeng et al (1974) also found that the globulins constitute 
a significant portion of plasma binding capacity in vitro at high PLP 
concentrations and that the total capacity of plasma to bind PLP is 
in the range of 3 mM, which far exceeds the normal plasma 
concentration of this vitamer. Dempsey (1962) points out however 
that at such supraphysiologic PLP concentrations, PLP binds 
nonspecifically to albumin in a ratio exceeding two to one. Thus, 
any calculation of the plasma PLP binding capacity at high PLP 
concentrations v/ill reflect binding potential not realized 
physiologically. 
Although the formation of Schiff bases is well known to be 
reversible, the reversibility of PLP binding to plasma proteins has 
been the source of some confusion. Christensen (1961) confirms the 
reversibility of the PLP-albumin Schiff base formation in his initial 
investigations. Lumeng, et al (1974), however, report tv/o 
conflicting experimental findings regarding the reversibility of 
Schiff base formation which they fail to resolve. They report the 
results of a dialysis experiment which appear to show that PLP bound 
to albumin is not dialyzable. A separate experiment in the same 
paper convincingly demonstrates, however, that virtually all of the 
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PLP bound to albumin is hydrolyzable by alkaline phosphatase whether 
the alkaline phosphatase is free in solution or separated from the 
PLP-albumin complex by a dialysis membrane. From the latter 
experiment they conclude that albumin bound PLP is indeed in 
equilibrium with free PLP in solution allowing membrane permeation by 
albumin bound PLP. However, without explanation, many of their 
subsequent conclusions (Lumeng et al 1980) are drawn by an inference 
from the first experiment that since PLP was found to be "non- 
dialyzable," it must therefore be irreversibly bound. For example, 
they state that Schiff base formation prevents PLP from being 
transported into erythrocytes. This may be true from a static 
viewpoint but may not be true in the actual dynamic equilibrium. The 
kinetics of PLP-albumin dissociation have not been adequately studied 
to establish this point. Furthermore, in a discussion of the fate of 
plasma PLP, they state that although PLP is found in the urine, it 
cannot arrive there by glomerular filtration since it's "not 
dialyzable." Clearly, the conceptual model derived from their 
dialysis experiment is a source of misdirection for themselves and 
perhaps others. 
Pyridoxal phosphate is the B6 vitamer which activates B6 dependent 
enzymes and it is also the vitamer found in the highest concentration 
in plasma. However, it is unclear if the PLP in plasma enters cells 
to combine with apoenzymes or whether another plasma vitamer enters 
tissues and activates apoenzymes after conversion to an active form. 
There remain two unexplained problems in the understanding of how 
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plasma PLP might enter cells. PLP is an organic phosphate and it is 
well recognized that such anions do not readily cross cell membranes 
without a specific transport mechanism. Such a mechanism has not 
been demonstrated for PLP. Also because the total plasma 
concentration of PLP is well below the plasma protein binding 
capacity for PLP, the amount of free PLP in solution may actually be 
less than any other B6 vitamer. This may not affect PLP transport, 
but it questions the logic of emphasizing PLP as the principle B6 
vitamer. Experiments directed at determining the relative enzyme 
activation potentials for the B6 vitamers, the actual free PLP 
concentration in plasma, and the mechanism of PLP transport across 
cell membranes are thus essential to understanding the physiology of 
b6- 
Experiments studying B6 metabolism at a cellular level have been 
carried out using cultured tumor cells (Pal and Christensen 1961), 
% ) 
rabbit choroid plexus (Spector and Greenwald 1978), and erythrocytes. 
Erythrocytes are the tissue upon which the majority of the literature 
is based. Whether the findings with erythrocytes can be generalized 
to the other cells of the body is not known; they remain nonetheless 
the model tissue for these investigations. 
The erythrocyte has several important properties affecting its 
metabolism of vitamin B6. Three enzymes, a phosphatase, a kinase, 
and an oxidase, have been identified in erythrocytes which appear to 
play an essential role in B6 metabolism. 
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Yamada and Tsuji (1968) first demonstrated a membrane bound 
phosphatase able to cleave PLP to PL and inorganic phosphate. 
Characterizing this enzyme, Lumeng and Li (1974) have shov/n that 80 
mM phosphate is inhibitory to the phosphatase activity. They also 
suggested that acetaldehyde, the ethanol metabolite, may potentiate 
the phosphatase. Their later work (Lumeng 1978) indicates that 
acetaldehyde may have this effect by displacing PLP from its 
protective protein binding. Mitchell et al (1976) also suggested 
from their in vivo studies in alcoholics that ethanol is responsible 
for increased PLP degradation and by inference increased phosphatase 
activity. Many of the experiments in the literature which focus on 
PLP transport into erythrocytes take advantage of the phosphate 
inhibition of the phosphatase to examine the role of this enzyme in 
Bs transport. The data derived from such experiments is analyzed 
with respect to alterations in the intracellular phosphorylated 
vitamer concentration. Unfortunately, it is also well documented 
that phosphate stimulates red cell glycolysis. This results in 
increased synthesis and decreased catabolism of ATP and other organic 
phosphates (Rose and Warms 1966, Beutler 1970, Warrendorf and 
Rubinstein 1973). The role this plays in altering B6 metabolism has 
not been investigated. 
The two enzymes necessary for interconversion of the B6 vitamers 
have been well studied. The enzyme pyridoxal kinase (EC 2.7.2.35) 
uses as substrate either ATP or ADP and is capable of phosphorylating 
PL, PM, and PN (McCormick et al 1961, Hamfelt 1967). It is 
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competitively inhibited by the substrate deoxypyridoxine (DOPM) which 
is itself slowly phosphorylated to DOPNP (McCormick and Snell 1961). 
Furukawa (1981) has also shown that, at least with microbial kinase, 
PL at high concentrations inhibits its activity by Schiff base 
formation at a non-active site. This inhibition, they note, is 
reversed by dialysis. Solomon and Hillman (1975) have investigated 
the in vivo regulation of pyridoxal kinase activity and find that 
orally administered PN induces increased kinase activity in young 
erythrocytes. 
The oxidase (EC 1.4.3.5) is an flavin-dependent enzyme which 
oxidizes PMP and PNP to PLP (Wada and Snell 1961). The non- 
phosphorylated vitamers, PM and PN are minimally reactive substrates. 
When Lumeng and Li (1974) measured the combined activities of the 
kinase and oxidase by measuring intracellular PLP concentration after 
incubation with PL, PN, or PNP, they found decreasing PLP content 
with increasing substrate concentrations. They concluded that the 
kinase or oxidase or both are subject to substrate inhibition. The 
investigations of the oxidase by Wada and Snell (1961) indicate the 
absence of substrate inhibition or inhibition by non-phosphorylated 
vitamers. 
Whether there are mechanisms for vitamin B6 homeostasis is 
unclear. The observed effects of substrates and products on the 
phosphatase, kinase, and oxidase are suggestive that these enzymes 
may play a role in maintaining homeostasis but this is presently 
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unresolved. 
Another important property of erythrocytes is the ability of 
hemoglobin to bind considerable quanitities of PL and PLP by 
reversible Schiff base formation. This has much the same 
sequestering effect on PL and PLP intracellularly that albumin has 
extracellularly. Borohydride reduction and further analysis have 
demonstrated that PL forms a Schiff base preferentially with the 
terminal amino group of the alpha-chain of hemoglobin and PLP with 
the beta-chain (Benesch et al 1973). Oxygen dissociation curves of 
hemoglobin in the presence of PL and PLP indicate that the binding of 
PL to hemoglobin lowers the p50 and PLP binding raises the p50 
(Benesch et al 1973). This and the finding that PL or PLP binding 
inhibits sickle hemoglobin polymerization have raised the question of 
using B6 in sickle cell patients to prevent erythrocyte sickling 
(Beutler et al 1972, Kark et al 1978). Although use of PN has not 
proven therapeutically fruitful, perhaps the use of other vitamers or 
modification of erythrocyte B6 metabolism would increase the effect 
of hemoglobin binding in vivo. 
Investigations in the current literature have examined some of 
these issues. For most, the assumption is made that since the total 
PLP content of plasma (including protein bound PLP) is the highest 
among the vitamers and since it is the active coenzyme, then PLP must 
by some means cross the cellular membrane. Because the erythrocyte 
has a membrane bound phosphatase able to cleave extracellular PLP (in 
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addition to intracellular PLP) to PL and a kinase intracellularly 
v/hich is able to resynthesize PLP from PL and ATP, many 
investigations over the past two decades have focused on the question 
asking whether PLP is transported across the membrane intact or is 
cleaved and reformed intracellarly. 
Suzue and Tachibana (1970) investigated this using a mixture of 
14C-PLP and 32P-PLP. They found the intracellular ratio of 14C to 
32P to be the same as the extracellular ratio and concluded from this 
that PLP must be transported intact across the cell membrane. They 
fail to elaborate on their reasoning but presumably if PLP were 
cleaved extracellularly and resynthesized intracellularly, the 
probability would be high that resynthesis would occur with non¬ 
radioactive phosphate. This v/ould cause an increase in the amount of 
14C-PLP relative to 32P-PLP intracellularly which they did not 
observe. 
Likewise, Spector and Greenwald (1978) attempted to show that 
accumulation of PLP in rabbit cerebrospinal fluid is dependent on a 
dephosphorylation-rephosphorylation mechanism. They found in vivo 
that intravenous injection of the doubly-labeled [3H,32P]-PNP 
resulted in accumulation of 3H-PLP in the CSF without accumulation of 
32P-phosphate. They also report that the accumulation of PLP in CSF 
is prevented by DOPN, the pyridoxal kinase inhibitor. This was 
attributed to the failure to resynthesize PLP once PL had entered the 
CSF. These experiments fails to discriminate, however, betv/een the 
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proposed mechanism of dephosphorylation prior to trans-membrane 
passage followed by rephosphorylation and the alternative that the 
phosphorylated vitamer may enter the CSF intact only to be subject to 
the activities of both a phosphatase and a kinase resulting in a net 
replacement of radioactive phosphate with non-radioactive phosphate. 
Using erythrocytes, Lumeng et al (1974) attempted to demonstrate 
that cleavage of PLP to PL by the membrane bound phosphatase is 
necessary for its transport across the cell-membrane. In normal 
saline they found 22% to the PLP added to the medium was 
intracellular after incubation whereas 38% remained extracellular. 
The remaining 40% of unrecovered PLP was presumed hydrolyzed by 
phosphatase. When the experiment was conducted with 80 mM phosphate 
to inhibit the phosphatase, 18% of the added PLP was still found 
intracellularly after incubation. Extracellularly, 77% of the added 
PLP was recovered leaving only 5% unrecovered thus indicating 
significant phosphatase inhibition. From this data they concluded 
that PLP cannot cross the erythrocyte membrane intact but that it 
must first be cleaved by phosphatase to PL. However, they fail to 
account for the 18% of PLP that enters the cells with the phosphatase 
"inhibited" versus the 22% with the phosphatase active. Indeed, this 
can be accounted for in two ways: either 80 mM phosphate does not 
fully inhibit phosphatase or another mechanism for transport of PLP 
into erythrocytes obtains. In either case, their conclusion that 
phosphatase activity is essential cannot be drawn with certainty from 
their data. In fact, Maeda et al (1976) concluded from their similar 
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experiments that intact PLP enters erythrocytes by passive diffusion. 
Using 160 mM phosphate buffer as an incubation medium, they 
demonstrated increasing intracellular PLP concentrations over time 
with minimal loss of total PLP in the system. Furthermore, they 
strengthen their argument for passive diffusion of PLP into 
erythrocytes by demonstrating that the initial velocity of PLP uptake 
is linear with respect to PLP concentration. 
The studies by Suzue and Tachibana (1968) and Maeda (1976) 
suggested PLP enters erythrocytes intact whereas the subsequent 
studies by Spector and Greenwald (1978) and Lumeng et al (1974) were 
not convincing that phosphatase activity is essential for transport. 
Thus a need for further investigation is clearly indicated. One 
mechanism by which PLP could enter tissues without prior cleavage is 
by direct passage through membrane anion channels. This has been 
investigated using anion channel blocking agents. 
Cabantchik and Rothstein (1974) developed the use of 
4,4!-diisothiocyano- 2,2'-stilbene disulfonic acid (DIDS) which they 
found to be a non-penetrating, highly specific and reactive blocker 
of erythrocyte anion channels. They later found that DIDS prevented 
membrane permeation by PLP (Cabantchik et al 1975). Further 
experiments characterizing the anion channel showed it is a single 
protein isolable in membrane vesicles (Wolosin et al 1977). Because 
DIDS binds to free amines, Cabantchik et al (1975) proposed that the 
anion channel protein has a free amino group as part of its active 
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site. And because PLP also binds to free amino groups, this group 
conducted experiments to determine the effect of PLP on the anion 
channel. They found that like DIDS, PLP could also inhibit the flux 
of anions across the membrane. Furthermore, they found that elution 
of the PLP from its binding sites reversed the effect on anion flux 
unless PLP was bound irreversibly to amines by borohydride reduction 
(Rothstein et al 1976). Interestingly, in their studies of sickle 
erythrocytes, Kark and Hicks (1930) found an increase in anion 
permeability of the membrane anion channels when compared to normal 
cells. This finding raises questions regarding how flux through the 
channels is regulated in the normal and abnormal erythrocyte and hov/ 
such regulatory mechanisms might affect passage of PLP through the 
membrane. 
One of the major impediments to progress in the field of B6 
physiology has been the development of an accurate means of measuring 
vitamer concentrations in the intracellular and extracellular 
environments. A number of different assays have been used including 
chemical, fluorometric (Chauhan and Dakshinamurti 1979), 
microbiological, and enzymatic. The direct chemical and fluorometric 
measurements are inherently difficult because of the low vitamer 
concentrations studied, the variable elution of PL and PLP from their 
protein binding sites, and the instability of certain vitamers. The 
microbiological techniques often lack specificity among vitamers or 
are insensitive to vitamers requiring assay. As a means of assessing 
the ability of a given vitamer to effect apoenzyme activation, the 
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enzymatic assays are quite useful. Erythrocytes contain readily 
measurable quantities of the PLP-dependent aspartate-oxaloacetate 
transaminase (EGOT, EC 2.6.1.1, Meister et al 1954, Walsh 1966). 
This enzyme is found to be only 50-70% saturated by cofactor in 
normal adults (Solomon and Hillman 1978) making it useful for in vivo 
and in vitro supplementation studies. It has been found that PMP is 
also able to activate EGOT but that PMP and DOPNP inhibit EGOT 
activity (Meister et al 1954). Furthermore, Solomon and Hillman 
(1975) demonstrated that orally administered PM can induce an 
increase in the total EGOT activity. Interestingly, they also 
observed a transient drop in EGOT activity within hours after oral PN 
or PLP administration. This was felt to be suggestive of reversible 
inactivation of the enzyme by non-specific Schiff base formation 
followed by redistribution to the active sites within a few days. 
They have also shown that in spite of a rapid rise in intracellular 
PL and PLP concentrations after an oral PN dose (Anderson et al 
1971), the rise in EGOT activity occurs 27-48 hours later (Solomon 
and Hillman 1979). This last finding in itself raises questions 
regarding the kinetics of the vitamer reactions and interactions 
which will be addressed later. 
Using the assay of EGOT as an index of PLP or PMP entry into 
tissues or entry of other vitamers followed by conversion to an 
active form, the experiments described here demonstrate that in 
plasma there is marked variation of EGOT activation by the various 
vitamers and that blocking the erythrocyte anion channels does not 
16 
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completely prevent entry of PLP into the cell. 
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II. EXPERIMENTAL 
All reagents were obtained from Sigma Chemical Co. with the 
exception of 3-(N-morpholino)propanesulfonic acid (MOPS) which was 
obtained from Calbiochem Inc., 4-acetomido, 4-isothiocyanostilbene 
2,21-disulfonic acid (SITS) and 
4,4'-diisothiocyanostilbene-2,21-disulfonic acid (DIDS) which were 
obtained from ICN Pharmaceuticals. 
Solutions of the B6 vitamers were made up to a concentration of 
approximately 45 mM, pH 7.40, and the actual concentrations were 
measured spectrophotometrically in the ultraviolet region (Storvick 
et al 1964). Aliguots of the solutions were stored frozen and thawed 
just prior to use. Solutions of 20 mM SITS and 0.5 mM DIDS in 
isotonic saline were made up just prior to use and kept protected 
from light at 0°C; , 
Freshly drawn heparinized blood from one of two healthy males was 
separated by centrifugation at lOOOg for 10 min at 7°C. The buffy 
coat was discarded and the RBC were washed with cold isotonic saline. 
The RBC were either used directly or preincubated at 0°C. in isotonic 
saline at a concentration of 30% (v/v) v/hich contained either 0.14 mM 
SITS or 0.035 mM DIDS. 
Incubation solutions of isotonic saline, 90% (v/v) heparinized 
plasma, or bovine serum albumin (BSA; 6 gm/dl NS) with 10 mM glucose 
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were buffered with MOPS, pH 7.40, to a final MOPS concentration of 
0.6 mM. Volumes of the vitamer solutions were added to give the 
final concentrations indicated in individual experiments. The values 
used for vitamer concentrations are calculated values based on the 
amount added to a given volumes of incubation solution. Thus they 
may not represent the actual free vitamer concentrations in the 
medium because of protein binding. In experiments employing SITS, a 
final concentration of 0.2 mM SITS in the incubation medium was used. 
Either normal RBC, or RBC preincubated with BIDS or SITS were 
resuspended in the incubation solutions to a concentration of 10% 
(v/v). The solutions were incubated at 37°C. in a shaking water bath 
and at timed intervals aliquots were removed, diluted with 7 volumes 
of ice cold isotonic saline, and centrifuged at 7°C. for 10 min at 
lOOOg. The pellet was washed with 90 volumes ice cold saline and 
recentrifuged under identical conditions. 
EGOT activity was assayed as follows according to the method 
described by Karmen et al (1955) and modified by Solomon (1978). The 
RBC were lysed by adding 30 ul of the washed RBC pellet to 3 ml of 
ice cold distilled water. After 10 min, 200 ul of the lysate was 
added to 2.6 ml of distilled water containing 33 mM d,1-aspartate, 
0.067 mg/ml DPNH, and 67 U/ml malate dehydrogenase. This mixture was 
preincubated 10 min in a shaking water bath at 37°C. Total EGOT 
activity was measured by including PLP at a concentration of 0.5 mM 
in the preincubaton solution and preincubating for 30 min. 
Thereafter, 200 ul of 100 mM alpha-ketoglutarate (in sodium phosphate 
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buffer, pH 7.5) was added and the consumption of DPNH was followed by- 
measurement of the decrease in optical density at a wavelength of 340 
nm over 20-30 min at 37°C using a Gilford spectrophotometer with an 
automatic chart recorder. Specific activity of EGOT is expressed as 
Units/g Hgb where one Unit is defined as the loss of optical density 
at 340 nm per minute divided by the extinction coeffecient for DPNH 
at 340 nm of 6.22. Lysate hemoglobin concentration was determined by 
the hemoglobincyanide method (van Kampen and Zijlstra 1961). 
When values were determined in triplicate, the mean is displayed 
graphically with the range of plus or minus one standard deviation. 
The significance of differences between means was analyzed by the 
method of Student's t test. 
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Ill. RESULTS 
To determine the relative abilities of the B6 vitamers to enter 
tissues from plasma and activate B6 dependent enzymes, erythrocytes 
were resuspended in 90% plasma containing PLP, PMP, PM, and PN and 
incubated for 6 hours. Aliquots removed at two hour intervals and 
assayed for EGOT activation showed marked variation in the relative 
abilities of the vitamers to effect GOT activation (fig 3). At 0.67 
mM, PLP did not significantly increase GOT activation above control 
levels. In contrast, the other vitamers were able to increase GOT 
activation at concentrations of 0.67 mM with PMP being the most 
active followed by PM. However, at a concentration of 3.3 mM, PLP 
almost completely activated EGOT. 
Since the total binding capacity of 90% plasma is probably in the 
range of 2.7 mM (Lumeng et al 1974), a PLP concentration of 3.3 mM 
would certainly provide a large amount of free PLP in solution. 
Thus, it's not surprising that at such a high concentration, this 
vitamer should be so active. Likewise, at 0.67 mM, the majority of 
PLP will be bound to albumin (and perhaps globulin) leaving a 
fraction free in solution that is quite small and unable to activate 
EGOT to the extent that the other vitamers do at 0.67 mM. 
These findings are consistent with those of Lumeng et al (1974) 
and Anderson (1971) who found that the presence of plasma prevents 
the entry of PLP into erythrocytes by virtue of binding to plasma 
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proteins. Of considerable interest then is the finding that other B6 
vitamers are able to enter the RBC and effect significant GOT 
activation. This finding questions the concept that PLP is the 
"principle" B6 vitamer because of its high plasma concentration. 
Rather, this experiment suggests that physiologic levels of other B6 
vitamers may enter tissues to a greater extent and effect a.poenzyme 
activation after conversion to active forms. Although PMP v/ould 
appear to be a strong possibility under these experimental 
conditions, it is found to constitute only 4% of the plasma B6 
vitamers (Table 1). Thus an experiment with PMP, PM and PN at 
equimolar concentrations does not accurately reflect the physiologic 
ratios of these vitamer concentrations. 
To confirm the theory that protein binding was responsible for the 
lack of GOT activation with 0.67 mM PLP in plasma, the previous 
experiment was performed in MOPS buffered isotonic saline. The 
> ) 
results (figs 4,5) clearly demonstrate that in the absence of plasma, 
0.67 mM PLP effects GOT activation almost to the same extent as 3.3 
mM PLP. Not surprisingly, PMP, PM and PN are as effective in 
activating GOT in saline as in plasma (figs 4,5). This confirms that 
plasma has no effect on these vitamers presumably because of their 
inability to form Schiff base adducts with plasma proteins. 
The effect of inorganic phosphate on EGOT activation by PLP in 
plasma was investigated using a low phosphate concentration (5 mM) 
and a moderately high concentration (20 mM). A higher concentration 
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of phosphate was not chosen because of the significant diminution of 
plasma volume this would require. Previous data (Solomon, 
unpublished data) indicates that at 20 mM, phosphate inhibits 
phosphatase activity by about 42%. At both concentrations however, 
phosphate was found to have no effect on the activation of GOT by 
either 3.8 mM PLP or 7.7 mM PLP (fig 6). This experiment would 
suggest that under these conditions, phosphatase activity is either 
not essential for transport of PLP into the erythrocyte at these 
concentrations or that the residual phosphatase activity is 
sufficient to mediate PLP uptake by dephosphorylation and duffusion 
of PL. 
To investigate an alternative mode of transport, the use of anion 
channel blocking agents was studied. Preincubating erythrocytes in 
0.035 mM DIDS resulted in significant alterations in apparent PLP 
uptake from plasma. In the presence of 1.8 mM PLP there was no 
significant difference distinguishable between the DIDS-treated cells 
and normal cells. However, at the higher PLP concentration of 3.5 
mM, further EGOT activation was noted in control cells but not in 
DIDS-treated cells (fig 7). This experiment was repeated with DIDS 
and v/ith another anion channel blocker, SITS, giving the same 
results. 
When the effects of DIDS and SITS on uptake of 11 mM PL and EGOT 
activation were investigated, no differences between normal cells and 
anion channel blocked cells v/ere found (fig 8). Interestingly, the 
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activation of EGOT by 3.5 mM PL is significantly less than the 
activation by 1.8 mM PLP (fig 7). This is contrary to what would be 
expected if cleavage of PLP to PL were the mechanism responsible for 
the non-anion channel dependent PLP transport. 
The results of the previous experiments using DIDS and SITS 
indicate anion channels may not be responsible for PLP transport at 
PLP concentrations less than 1.3 mM. To further characterize the 
non-anion channel dependent PLP transport, an experiment was carried 
out comparing normal cells to DIDS treated cells using a suspension 
medium of bovine serum albumin (6 gm/dl) and glucose (10 mM) in 
isotonic MOPS buffered saline. The results (fig 9) show that DIDS 
did not inhibit EGOT activation when the PLP concentration in the 
medium v/as 2.4 mM. In contrast, incubation with 4.8 mM PLP did not 
further increase EGOT activation in DIDS treated cells. This 
reproduces the observations made using plasma indicating that there 
% l 
is not some previously unrecognized element of plasma such as free 
amino acids which partakes in PLP transport. 
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glucose (10 mM) in isotonic saline after 4 hours incubation. 
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IV. DISCUSSION 
This study investigated several critical issues in vitamin B6 
metabolism using activation of erythrocyte aspartate-oxaloacetate 
transaminase (EGOT) as an indicator of intracellular cofactor 
availability to vitamin B6 dependent enzymes. A comparison of the 
relative abilities of the various vitamers to enter the erythrocyte 
and effect EGOT activation demonstrated the inability of PLP to enter 
the erythrocyte from plasma whereas other vitamers, particularly PMP, 
were quite active. 
Previous investigations of PLP entry into the erythrocyte have 
also shown that it is not readily transported across the cell 
membrane from plasma (Anderson et al 1971, Lumeng et al 1974). This 
observation which was confirmed here questions the importance 
generally accorded to PLP. The activities of the other vitamers as 
shown in figure 2 are in fact much greater than equimolar PLP. This 
raises the important question of which of these could play an 
important role in vivo. 
Because of serum protein binding, plasma PLP is unable to enter 
erythrocytes in significant amounts in these experiments and also in 
the experiments of other investigators. It is unclear however 
whether these events accurately reflect events in vivo. One critical 
assumption is essential to the conclusions drawn from these 
experiments. To claim that PLP remains in plasma because it binds to 
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plasma proteins preferentially over intracellular or membrane binding 
sites requires an assumption that equilibrium is reached during the 
incubation period of these experiments. This has not been 
established. In fact, data of previous investigators suggest that 
PLP may not reach equilibrium within hours but rather over days. For 
instance, in the experiments of Lumeng (1973), continued loss of PLP 
from plasma occurs during dialysis over the entire 24 hour period 
studied. Thus the time course of dissociation is quite slow. 
Similarly, dialysis of liver cytosol over 24 hours liberated only 20% 
of hepatic cytosolic PLP from holoenzyme complexes. If it is assumed 
that all PLP is reversably bound to enzymes, then this dissociation 
is also quite slow. The in vivo investigations of Solomon and 
Hillman (1979) clearly shov; an unexplained 24-48 hour delay between a 
single oral PN dose and a rise in EGOT activity. Solomon and Hillman 
(1979) proposed that the initial drop in EGOT within hours of 
intramuscular PLP or, oral PN administration followed by a rise after 
days was due to non-specific inhibitory binding of PLP to the enzyme 
followed by redistribution to the active sites. Thus a delay of days 
is seen in the response of EGOT to increased PLP in several different 
experimental settings. One possible explanation for this is that PLP 
added to plasma, whether in vivo (from liver or by injection) or in 
vitro, requires days to dissociate from serum proteins and reach the 
active sites of apoenzymes. Thus, before more conclusions can be 
drawn regarding the thermodynamics of PLP binding, certain 
assumptions regarding the binding kinetics clearly must be 
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substantiated or revised. 
The investigations of membrane permeation by PLP using DIDS are 
intriguing. Although Cahantchik (1975) reports that the anion 
channel blocking agent DIDS totally prevents PLP entry into 
erythrocytes, the experiments here demonstrate that there is a 
distinct component of PLP transport which is not affected by anion 
channel blockers. This effect is apparent at PLP concentrations in 
the 1.0-1.5 mM range. This is well below the binding capacity of 
plasma for PLP which means that the actual amount of PLP free in 
solution is probably fairly low. Only when the plasma content of PLP 
is near or above the binding capacity for this vitamer is DIDS 
blockable transport observed. In this case, the concentration of 
free PLP in the medium is much higher and it is only then that the 
anion channels appear to play a role in transmembrane PLP passage. 
Apparently, in the more physiologic situation of lov; PLP 
concentrations, a mechanism for PLP transport other than anion 
channels obtains. Investigation of the dephosphorylation- 
rephosphorylation mechanism may help resolve this issue. Such 
experiments would best be done by inhibiting the phosphatase which is 
essential to this mode of transport. The experiments conducted here 
show that at 5 mM and 20 mM, phosphate has no effect on PLP 
activation of EGOT in spite of its demonstrated inhibitory effect on 
the phosphatase. Unfortunately, any results found using phosphate 
may be confused by the effect phosphate also has intracellularly of 
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raising concentrations of organic phosphate esters. A better 
inhibitor of the phosphatase is thus critically important to further 
examine this postulated mechanism. 
Yet another possible mechanism of PLP transport might be coupling 
with amino acid transport. That membranes have specific mechanisms 
for amino acid transport has been well documented (Guidotti et al 
1978). Felig et al (1973) have also shown that erythrocytes may act 
as a transport form of amino acids. One could hypothesize that amino 
acid uptake and PLP uptake by erythrocytes are interrelated, perhaps 
by Schiff base complexing between the two and transport of the 
adduct. However, the experiment described here using a medium of 
bovine serum albumin and glucose instead of plasma suggests that free 
amino acids found in plasma are not responsible for the non-anion 
channel dependent PLP uptake. On the other hand, no one has 
conclusively shov/n how PLP is released from hepatocytes and although 
it is proposed that it does so bound to albumin (Lumeng and Li 1980) 
the possibility that an amino acid-PLP Schiff base is the released 
form merits investigation. Although Gregory and Kirk (1978) once 
suggested that pyridoxyllysine may exert an anti-B6 activity, this 
claim has not been substantiated. Thus the possibility that amino 
acid-PLP adducts could play an important role physiologically or even 
pharmacologically deserves further attention. 
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V. CONCLUSION 
Although a few questions are answered here, many more questions 
are raised. It is clear that under the experimental conditions 
employed, there is marked variability in the activation of a tissue 
enzyme, EGOT, by the various B6 vitamers. It is also clear that 
blockade of membrane anion channels can alter membrane permeability 
of PLP. But contrary to v/hat was previously found, this does not 
occur at PLP concentrations near the physiologic range. 
Further elucidation of the mechanisms involved in PLP transport 
into tissues would thus be essential. Only with such knowledge can 
therapeutically advantageous manipulations of PLP transport be 
designed. That PLP is actually the B6 vitamer deserving this 
concentrated attention is, unfortunately, also unresolved. Although 
the experiments here; confirm the inability of PLP to enter tissues 
from plasma and further demonstrate that PMP and PM are quite active, 
a serious issue of kinetics of this interaction is questioned. 
Thus, before any more theories regarding the behavior of PLP in 
plasma are asserted, conclusive experiments addressing the time 
course of the PLP-plasma interactions are imperative. Because the 
studies previously cited indicate that PLP may equilibrate with 
plasma over days instead of hours, it remains distinctly possible 
that PLP is indeed the B6 vitamer which enters tissues from plasma to 
activate the B6-dependent enzymes. This certainly would not have 
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been demonstrated in these experiments or those of previous 
investigators because of v/hat may be grossly insufficient in vitro 
incubation periods. 
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